FibroGen Inc
$ 8.90
3.67%
26 Dec - close price
- Market Cap 36,004,500 USD
- Current Price $ 8.90
- High / Low $ 9.00 / 8.36
- Stock P/E N/A
- Book Value -4.21
- EPS -12.85
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -10.16 %
- 52 Week High 21.94
- 52 Week Low 4.85
About
FibroGen, Inc. is a San Francisco-based biopharmaceutical company focused on developing innovative therapies targeting chronic kidney disease and fibrotic diseases. Leveraging its proprietary technology platforms, FibroGen aims to deliver novel therapeutics that meet significant unmet medical needs and improve patient outcomes. The company's strong pipeline, supported by cutting-edge research and strategic partnerships, positions it for growth as it seeks to transform healthcare solutions for patients globally. With a commitment to innovation and patient-centric care, FibroGen is poised to make a meaningful impact in the biopharmaceutical landscape.
Analyst Target Price
$43.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-05 | 2025-02-24 | 2024-11-04 | 2024-08-06 | 2024-05-06 | 2024-02-26 | 2023-11-06 | 2023-08-07 | 2023-05-08 | 2023-02-27 |
| Reported EPS | -3.25 | -3.39 | 0.05 | -0.08 | 0.0146 | -0.16 | -0.33 | -0.57 | -0.52 | -0.9 | -0.81 | -0.7 |
| Estimated EPS | -0.095 | -0.09 | 0.02 | -0.2 | -0.3 | -0.32 | -0.42 | -0.42 | -0.68 | -0.7 | -0.75 | -0.94 |
| Surprise | -3.155 | -3.3 | 0.03 | 0.12 | 0.3146 | 0.16 | 0.09 | -0.15 | 0.16 | -0.2 | -0.06 | 0.24 |
| Surprise Percentage | -3321.0526% | -3666.6667% | 150% | 60% | 104.8667% | 50% | 21.4286% | -35.7143% | 23.5294% | -28.5714% | -8% | 25.5319% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: FGEN
2025-12-24 00:09:59
FibroGen's stock saw an increase after roxadustat, its anemia drug candidate, was granted orphan drug status by the U.S. Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS). This designation provides incentives for developing treatments for rare conditions. Roxadustat is already approved in China for anemia associated with chronic kidney disease.
2025-12-19 11:10:11
FibroGen (FGEN) shares advanced after its drug roxadustat received orphan drug designation from the FDA for pediatric patients with end-stage renal disease (ESRD). This designation aims to encourage the development of drugs for rare diseases by providing incentives such as tax credits and waived fees. Roxadustat is an oral HIF-PHI that aims to treat anemia in CKD patients.
2025-12-17 02:10:13
FibroGen (NASDAQ:FGEN) shows a relatively safe balance sheet with net cash of US$98.5m, offsetting its debt. Despite being a relatively new revenue-generating company that is currently unprofitable, burning US$17m cash and losing US$52m over the last year, its significant cash reserves provide a buffer for over two years at its current spending rate. While its balance sheet appears liquid, the lack of consistent free cash flow categorizes it as a somewhat risky investment.
2025-12-16 10:09:06
FibroGen (NASDAQ:FGEN) utilizes debt but also holds significant cash, resulting in a net cash position of US$98.5m. While the company is currently unprofitable and has burned cash, its strong liquidity—having more liquid assets than total liabilities—suggests it can manage its debt safely, despite the inherent risks of being a loss-making company. Investors should consider its financial health and future earnings forecasts.
2025-12-16 02:10:57
FibroGen's stock rose 3% after its drug roxadustat was granted Orphan Drug Designation by the U.S. FDA for treating myelodysplastic syndromes (MDS). This designation offers benefits like fee exemptions, development incentives, and market exclusivity. Roxadustat targets a significant treatment gap in MDS patients, particularly for anemia, and the company is finalizing a Phase 3 protocol for FDA submission in Q4 2025.
2025-12-15 14:09:10
FibroGen (FGEN) stock rose after its drug roxadustat received orphan drug designation for chronic pancreatitis from the FDA. This designation provides incentives such as tax credits and waived fees, potentially accelerating the drug's development. Roxadustat is currently approved in other regions for anemia in chronic kidney disease patients.
